Predicting Antiretroviral Drug Resistance from the Latest or the Cumulative Genotype

Gazzard B.G. , Anderson J. , Babiker A. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

Hammer S.M. , Eron J.J. Jr. , Reiss P. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555–570.

The Department of Health and Human Sciences Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. (Updated 10 January 2011. Accessed 7 March 2011.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.

Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007; 20: 22–32.

Phillips A.N. , Dunn D. , Sabin C. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487–494.

Fox Z.V. , Geretti A.M. , Kjaer J. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 2007; 21: 2033–2042.

Johnson J. , Geretti A.M. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 2010; 65: 1322–1326.

Grant P.M. , Zolopa A.R. The use of resistance testing in the management of HIV-1-infected patients. Curr Opin HIV AIDS 2009; 4: 474–480.

Yahi N. , Tourres C. , Tivoli N. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs. AIDS 2000; 14: 2943–2945.

Palmer S. , Kearney M. , Maldarelli F. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406–413.

Geretti A.M. , Fox Z.V. , Booth C.L. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52: 569–573.

Halvas E.K. , Wiegand A. , Boltz V.F. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 2010; 201: 672–680.

Briones C. , Domingo E. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev 2008; 10: 93–109.

Wainberg M.A. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004; 2: 147–151.

Kolber M.A. Development of drug resistance mutations in patients on highly active antiretroviral therapy: Does competitive advantage drive evolution. AIDS Rev 2007; 9: 68–74.

Johnson V.A. , Brun-Vezinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008; 16: 62–68.

Petrella M. , Oliveira M. , Moisi D. , Detorio M. , Brenner B.G. , Wainberg M.A. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother 2004; 48: 4189–4194.

Geretti A.M. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006; 8: 210–220.

Marcelin A.G. , Flandre P. , Pavie J. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49: 1739–1744.

McColl D.J. , Margot N.A. , Wulfsohn M. , Coakley D.F. , Cheng A.K. , Miller M.D. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2004; 37: 1340–1350.

Margot N.A. , Enejosa J. , Cheng A.K. , Miller M.D. , McColl D.J. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009; 52: 209–221.

Geretti A.M. Shifting paradigms: the resistance profile of etravirine. J Antimicrob Chemother 2008; 62: 643–647.

Vingerhoets J. , Tambuyzer L. , Azijn H. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24: 503–514.

Varghese V. , Shahriar R. , Rhee S.Y. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009; 52: 309–315.

Ruxrungtham K. , Pedro R.J. , Latiff G.H. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9: 883–896.

Talbot A. , Grant P. , Taylor J. Predicting tipranavir and darunavir resistance using genotypic, phenotypic and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother 2010; 54: 2473–2479.

Harrigan P.R. , Wynhoven B. , Brumme Z.L. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191: 1325–1330.

Zaccarelli M. , Lorenzini P. , Ceccherini-Silberstein F. Historical resistance profile helps to predict salvage failure. Antivir Ther 2009; 14: 285–291.

Zazzi M. , Prosperi M. , Vicenti I. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother 2009; 64: 616–624.

De Luca A. , Cozzi-Lepri A. , Perno C.F. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antivir Ther 2004; 9: 743–752.

Steigbigel R.T. , Cooper D.A. , Teppler H. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605–612.

Gulick R.M. , Lalezari J. , Goodrich J. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429–1441.